Puberty Blockers Trial Cleared On NHS
A landmark clinical trial examining the use of puberty-blocking drugs in gender-questioning children can begin recruiting participants from August after the High Court rejected a legal challenge seeking to halt it.
On 31 July 2026, Mr Justice Chamberlain refused permission for a full judicial review, ruling that none of the campaigners’ claims had a realistic prospect of success. The decision clears the way for the NHS-funded Pathways trial, run by King’s College London, to start enrolling children.
The trial forms the centrepiece of efforts to generate high-quality evidence on puberty blockers (gonadotrophin-releasing hormone analogues) following the 2024 Cass Review. That independent review, led by paediatrician Baroness Hilary Cass, concluded that the evidence base for using the drugs to treat gender incongruence or dysphoria in young people was “remarkably weak.” In response, NHS England ended the routine prescription of puberty blockers for under-18s. New prescriptions were restricted to carefully controlled research settings.
Pathways is a randomised controlled trial designed to fill that evidence gap. It aims to recruit 226 children and young people under 16 who are already accessing specialist NHS gender services and have a diagnosis of gender incongruence. Participants will be randomly assigned to one of two groups: one receives puberty blockers immediately for up to 24 months; the other waits 12 months before starting treatment. Researchers will track effects on quality of life, mental health, body satisfaction, bone density, brain development, fertility and other physical outcomes.
Eligibility requires extensive prior assessment by specialist teams over many months. Girls must be at least 11 and boys at least 12. These minimum ages were introduced after the Medicines and Healthcare products Regulatory Agency (MHRA) paused the trial in February 2026 over safety concerns and recommended a higher threshold. Protocol changes strengthened information provided to families about potential risks, including impacts on fertility and bone health, before the trial received fresh regulatory approval.
Campaigners who brought the legal challenge — including detransitioner Keira Bell, psychotherapist James Esses and the Bayswater Support Group of parents — argued that the safeguards remained inadequate. They raised concerns about long-term physical and psychological effects and questioned whether children could give truly informed consent to experimental treatment.
Keira Bell, who was prescribed puberty blockers as a teenager before later detransitioning, described the court’s decision as “a tragedy,” saying medical practice and morality do not always align. The Bayswater group expressed disappointment at the study’s design and the level of protection for minors.
Supporters of the trial, including researchers and some clinicians, argue it is essential precisely because the evidence is so limited. Baroness Cass herself has described rigorous research of this kind as necessary. A spokeswoman for King’s College London said the safety and welfare of young people remain the highest priority, with independent oversight committees monitoring the study. The Health Research Authority also welcomed the legal scrutiny, stating that ethics reviews and regulatory checks exist to protect participants.
The ruling does not change the broader ban on routine prescribing outside research. Existing patients already on puberty blockers have been allowed to continue. Results from Pathways are expected to inform future policy, including a planned review of the restrictions.
The case has drawn intense public and political attention, reflecting deep divisions over how best to support children experiencing gender distress. Campaigners on both sides say the world is watching the UK’s approach. Recruitment is now due to begin in the coming days, marking a significant moment in one of the most contested areas of paediatric medicine.
